5 Fastest Growing Tech Penny Stocks to Buy

4. Autolus Therapeutics plc (NASDAQ:AUTL)

On July 1, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) announced that the Compensation Committee of its Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units to 13 employees under the company’s 2025 Inducement Plan. The awards were granted as inducement material to the individuals becoming employees of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option awards and RSUs have a grant date of June 24, 2026. The stock options have an exercise price of $1.66 per share, equal to the closing price of Autolus’ common stock on June 23, 2026. Each stock option award has a ten-year term and vests over four years, while each RSU vests in four equal annual installments, subject to continued service through the applicable vesting dates.

Over a month ago, H.C. Wainwright raised the firm’s price target on Autolus Therapeutics to $10 from $9 and kept a Buy rating on the shares after the Q1 report. H.C. Wainwright said the company’s Aucatyzl U.S. demand is growing, while the UK launch is off to a positive start.

Autolus Therapeutics plc (NASDAQ:AUTL) develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.

1281292 - 11759070 - 1